Clinical trials: Psoriasis Patients
Plaque Psoriasis
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
The aims is to evaluate the efficacy and comparative isolation of the association Mometasone furoate + Salicylic Acid and the substance isolated Mometasone furoate produced by the Laboratory Glenmark Pharmaceuticals Ltd.
- Trial name
- Psoriasis (NCT01228656)
- Testing
- mometasone furoate + salicylic acid, Mometasone furoate
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris
This study will evaluate the efficacy and safety of calcipotriol plus betamethasone dipropionate ointment compared with calcipotriol ointment in the treatment of patients with psoriasis vulgaris for a duration of 4 weeks.
- Trial name
- NCT00248456
- Testing
- Calcipotriol plus betamethasone dipropionate ointment
- Where
- China
- Volunteers
- 320 people
- Sponsor
- LEO Pharma
Psoriasis
Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis
A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients with Severe, Recalcitrant, Plaque Type Psoriasis.
- Trial name
- NCT00236119
- Testing
- CEP-701 20mg, CEP-701 40mg, CEP-701 60mg
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Cephalon
Psoriasis, Healthy
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people.
- Trial name
- NCT07850310
- Testing
- MK-8644
- Where
- Australia
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
- Trial name
- AgAIN (NCT04632927)
- Testing
- Secukinumab, Ustekinumab
- Where
- 28 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )
This study is a Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis.
- Trial name
- NCT07746479
- Testing
- LZM012
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Moderate to Severe Plaque Psoriasis
Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.
- Trial name
- NCT02607774
- Testing
- Midazolam, AIN457
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque Psoriasis
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
This is a Phase IIa, randomised, double-blind, placebo-controlled, multiple dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.The objectives of this study is to investigate…
- Trial name
- AbGn-168H (NCT01855880)
- Testing
- AbGn-168H
- Where
- 15 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Psoriasis
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
The primary objective of the trial is to assess the PK similarity between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT03210259
- Testing
- Humira®, BI 695501
- Where
- 49 sites in United States, Germany and 5 more
- Volunteers
- 259 people
- Sponsor
- Boehringer Ingelheim
Psoriasis, Stress
12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN
This is a 12-Week, multicenter, double-blind, controlled, randomized study assessing change in psoriasis severity and level of stress in patients with moderate to severe psoriasis treated with TEN.
- Trial name
- NCT03511755
- Testing
- Transdermal Electrical Neuromodulator (TEN)
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Thync Global, Inc.
Rheumatoid Arthritis, Ankylosing Spondylarthritis
Yuflyma® (Adalimumab), Patient Experience After Switching
Patient preference and experience can impact patients' adherence and persistence regarding a treatment, especially when switching.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylarthritis, Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- YU-MATTER (NCT05427942)
- Testing
- Adalimumab
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Celltrion HealthCare France
Psoriasis
Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
Psoriasis (PsO) is a chronic, disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques and is associated with high burden of illness that results in a negative impact on long-term health…
- Trial name
- NCT04818385
- Where
- 8 sites in Taiwan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis
The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis
- Trial name
- NCT00195689
- Testing
- Human anti-TNF monoclonal antibody/adalimumab
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Abbott
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
- Trial name
- ENDURE (NCT01090310)
- Testing
- AIN457
- Where
- 35 sites in United States, Brazil and 6 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
- Trial name
- UNCOVER-3 (NCT01646177)
- Testing
- 50 mg etanercept, 80 mg ixekizumab
- Where
- 101 sites in United States, Argentina and 8 more
- Volunteers
- 1,346 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Palmoplantar Pustulosis
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab.
- Trial name
- NCT04493424
- Testing
- Spesolimab
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Moderate and Severe Plaque Psoriasis
Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis
This is a study in patients with moderate to severe chronic plaque psoriasis.All the participants will be randomized into three groups, high-dose UC-MSCs, low-dose UC-MSCs, or methotrexate group.This study is designed to prove…
- Trial name
- NCT03424629
- Testing
- Low-dose UC-MSCs, High-dose UC-MSCs, Methotrexate
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Tianjin Ever Union Biotechnology Co., Ltd.
Spondylitis, Ankylosing, Arthritis, Rheumatoid
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
The purpose of this observational study is to evaluate the safety and effectiveness of infliximab injection under actual conditions of use in participants, and to learn more about its adverse events.
- Conditions
- Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis, Arthritis, Psoriatic
- Trial name
- NCT00760669
- Testing
- Infliximab; observational study, Methotrexate; observational study
- Volunteers
- 1,061 people
- Sponsor
- Janssen Korea, Ltd., Korea
Arthritis, Psoriatic
Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)
This will be a Canadian observational study utilizing a prospective cohort design. Patients with active psoriatic arthritis (PsA) for whom the treating physician has decided, prior to and independently of enrollment in the study…
- Trial name
- APPRAISE (NCT03608657)
- Testing
- Apremilast
- Where
- 19 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Amgen